Counting rules and out-of-pocket payment under Japan’s 2026 high-cost medical expense reform: a simulation of breast cancer treatment courses

Abstract Background. Japan’s high-cost medical benefit caps monthly out-of-pocket payment by income and lowers the cap from the fourth qualifying month. The August 2026 reform raised the monthly caps, kept the lower cap, and added an annual cap over a fixed August–July year. We estimated its effect on what breast cancer patients pay. Methods. We simulated 15 courses before and after the reform by income category, start date, and brand or generic pricing. The benchmark was the increase for a patient who reaches the monthly cap every month: three months’ rise in the cap, 4,500 to 51,330 yen (US$28–323) across five income categories. Results. Of 60 combinations of one-year course and income category, payment was unchanged in 16, mostly endocrine courses; rose by no more than the benchmark in 26, mostly surgery and chemotherapy courses; and rose or fell with the course start in 18. The increase exceeded the benchmark in 8 of the 60, 7 in the two highest categories and none in the two lowest, reaching 409,840 yen (US$2,578) against a benchmark of 51,330 yen (US$323). Decreases, up to 664,647 yen (US$4,180), came only from the annual cap, reached in 1,423,481 of 21,475,422 course-years. Generic or biosimilar substitution, though cheaper, raised the annual payment in 23.30% of 51,873 upper-middle-category pairs (median across start days). Conclusions. The reform adds little or nothing for endocrine treatment, surgery, and standard chemotherapy. For year-long high-cost courses, the effect depends on income and start month, and a cheaper drug can cost the patient more.

Authors

Institutions

Publication Details

Journal
Research Square
Published
2026-11-13
DOI
https://doi.org/10.21203/rs.3.rs-11410504/v1
Primary Topic
Economic and Financial Impacts of Cancer
Type
preprint
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
preprint

Counting rules and out-of-pocket payment under Japan’s 2026 high-cost medical expense reform: a simulation of breast cancer treatment courses

Akihiko Ozaki, Yudai Kaneda, Tomohiro Kurokawa, Masanori Oshi et al.
1 links
Research Square
Economic and Financial Impacts of Cancer
preprint

Counting rules and out-of-pocket payment under Japan’s 2026 high-cost medical expense reform: a simulation of breast cancer treatment courses

Akihiko Ozaki, Yudai Kaneda, Tomohiro Kurokawa, Masanori Oshi, Tohru Ohtake, Yoshinori Nakata, Mika Nashimoto, Masaru Noda, Kenji Gonda, Toyoaki Sawano, Masahiro Wada, Hiroaki Shimmura, Kazunoshin Tachibana, Akemi Hara, Ayu Ajitomi
preprint en

Abstract

Abstract Background. Japan’s high-cost medical benefit caps monthly out-of-pocket payment by income and lowers the cap from the fourth qualifying month. The August 2026 reform raised the monthly caps, kept the lower cap, and added an annual cap over a fixed August–July year. We estimated its effect on what breast cancer patients pay. Methods. We simulated 15 courses before and after the reform by income category, start date, and brand or generic pricing. The benchmark was the increase for a patient who reaches the monthly cap every month: three months’ rise in the cap, 4,500 to 51,330 yen (US$28–323) across five income categories. Results. Of 60 combinations of one-year course and income category, payment was unchanged in 16, mostly endocrine courses; rose by no more than the benchmark in 26, mostly surgery and chemotherapy courses; and rose or fell with the course start in 18. The increase exceeded the benchmark in 8 of the 60, 7 in the two highest categories and none in the two lowest, reaching 409,840 yen (US$2,578) against a benchmark of 51,330 yen (US$323). Decreases, up to 664,647 yen (US$4,180), came only from the annual cap, reached in 1,423,481 of 21,475,422 course-years. Generic or biosimilar substitution, though cheaper, raised the annual payment in 23.30% of 51,873 upper-middle-category pairs (median across start days). Conclusions. The reform adds little or nothing for endocrine treatment, surgery, and standard chemotherapy. For year-long high-cost courses, the effect depends on income and start month, and a cheaper drug can cost the patient more.

Research Square
University of North Carolina at Chapel Hill (US), Fukushima Medical University (JP), Yokohama City University Hospital (JP), Jyoban Hospital of Tokiwa Foundation (JP), Kameda Medical Center (JP), Teikyo University (JP)
Good health and well-being
Economic and Financial Impacts of Cancer
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon